Abstract:7097 Background: Recently, two studies by Paez and Lynch show that somatic mutations in EGFR tyrosine kinase(TK) domain are associated with sensitivity of NSCLC to gefitinib. The mutations were clustered around ATP-biding pocket of the TK domain. Mutations were more frequent in women, adenocacinomas or bronchoalveolar carcinoma (BAC) and non-smoker patients. Interestingly, these studies showed the frequency of mutations is 2%–8% in Caucasian patient population compared to 26% in Japanese patients. Pao also report that 88% of these mutations are located at two “hotspots”(exon 19 and 21). This result also prompted us to perform analysis of EGFR mutations particularly on exon 19 and 21 in Chinese patients. Methods: All patients were pathologically confirmed NSCLC who had not been exposed to gefitinib. Fresh frozen tumor specimens and matched normal tissue were obtained from 56 consecutive patients during surgical operation. DNA was isolated by Proteinase K digestion, followed by traditional Phenol-chloroform extraction procedures. PCR was performed using the Takara Taq™ system (Takara Bio, Otsu, Japan). PCR amplification fragments were then sequenced and analyzed in both sense and antisense directions, using Beckman Coulter CEQ8000 Genetic analysis system and the CEQ™ DTCS Quick Start Kit (Beckman Coulter). Results: Somatic mutations in the TK domain of EGFR were identified from 9 of 56 (16.1%) patients. Among the 9 mutants, 6 showed in-frame deletions in exon 19 (delE746-A750 and delL747-S752). Another 3 showed substitutions leucine to arginine at position 858 (L858R) in exon 21. Mutations were more frequent in BAC (40%) and adenocarcinoma (28%) than in squamous carcinoma (0%), more frequent in women (21.4%) than in men (14.3%), and more frequent in non smokers (23.8%) than in smokers (11.4%). The highest fraction of mutations was detected in women with adenocarcinoma (42.9%). Conclusions: The status of EGFR mutations on exon 19 and exon 21 in Chinese patients with NSCLC are similar to Japanese patients, and the frequency of EGFR mutations in Chinese patients is higher than that in Caucasian patients (16.1% vs 2–8%). No significant financial relationships to disclose.

Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer

Epidermal Growth Factor Receptor Mutations Detected in Tumors from Chinese “never Smokers”with Lung Adenocarcinoma

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

The Status of Epidermal Growth Factor Receptor (EGFR) Mutations at Exon 19 and 21 in Chinese Patients with NSCLC

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients

Analysis of EGFR Mutation in Chinese Non-Small Cell Lung Cancer Patients

[Mutations in Exon 19 of EGFR Gene in Non-Small Cell Lung Cancer from Chinese Patients].

[Epidermal Growth Factor Receptor Gene Mutations and Clinicopathologic Correlation in 309 Patients with Non-Small Cell Lung Cancer].

[Relationship Between EGFR and K-ras Mutations and Clinicopathological Characteristics and Response to Erlotinib Treatment in 301 Chinese Patients with Non-Small Cell Lung Cancer].

Mutations of the epidermal growth factor receptor gene in NSCLC patients.

Epidermal growth factor receptor mutations in Chinese patients with adenocarcinoma of the lung

Mutational Analysis of EGFR in Chinese Patients with NSCLCs

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Clinical significance of EGFR mutations in non-small cell lung cancer

Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).